Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations

Ítems similars

• Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
  per: Liu, Sangtian, et al.
  Publicat: (2021)
• Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
  per: Shi, Jinpeng, et al.
  Publicat: (2017)
• Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer
  per: Gao, Guanghui, et al.
  Publicat: (2019)
• MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type
  per: Li, Jiayu, et al.
  Publicat: (2014)
• Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
  per: Li, Xuefei, et al.
  Publicat: (2016)